Advanced Models of Parkinson’s Disease



Optimized cell lines are essential for modeling neurodegenerative diseases such as Parkinson’s disease, screening novel therapeutics for preclinical studies, and testing the neurotoxicity of environmental compounds. Neural progenitor cells (NPCs) derived from induced pluripotent stem cells (iPSCs) are excellent in vitro models as they can be induced to differentiate down all three neural lineages. ATCC has recently added a line of NPCs developed from a donor with Parkinson’s disease to its collection of neurological research tools. This webinar will describe how ATCC NPCs can be differentiated into three neural fates and used in toxicological studies, focusing on the performance of the Parkinson’s disease-derived NPCs.

Key Points:

  • ATCC has a wide range of whole-cell models of Parkinson’s disease
  • NPCs cultured in ATCC Dopaminergic Neuron Differentiation Media express tyrosine hydroxylase and TuJ1
  • Parkinson’s disease patient-derived NPCs can be induced to differentiate into all three major neural lineages
  • Parkinson’s disease patient-derived NPCs can be used to screen compounds for toxicity


Brian Shapiro

Brian Shapiro, Ph.D.,
Scientific Content Specialist, ATCC

Brian A Shapiro, Ph.D., works to communicate the scientific breakthroughs of ATCC’s product development laboratories to the biomedical research community. Previously, he worked at Virginia Commonwealth University, where he investigated the role of pre-mRNA splicing in the multi-drug resistance of lung cancer. Dr. Shapiro attended the Medical College of Georgia, where his research focused on adrenal physiology as well as diseases of the epidermis.